AI-generated research brief — verify at source
Phase III Trial Launched to Test Whether Adding Flucytosine to Fluconazole Cuts Mortality in HIV-Associated Cryptococcal Antigenaemia
A registered phase III randomised controlled trial is enrolling 600 adults with HIV-associated cryptococcal antigenaemia to determine whether a 14-day oral induction regimen of fluconazole plus flucytosine reduces all-cause mortality at six months compared with fluconazole alone, with the trial powered to detect a 40% relative reduction in mortality (91% power). No efficacy results are yet available, as this publication describes the trial protocol and design rather than outcomes.
What Was Studied
The trial investigates whether adding flucytosine (100 mg/kg/day) to high-dose fluconazole (1200 mg/day) for a 14-day induction period is superior to fluconazole monotherapy in reducing all-cause mortality at six months among adults with blood cryptococcal antigen (CrAg) positivity but no clinical evidence of meningitis. The question is motivated by evidence that current standard fluconazole pre-emptive treatment, while reducing meningitis incidence, leaves a residual excess mortality in CrAg-positive individuals compared with CrAg-negative peers, and that cryptococcal disease continues to appear as a cause of death at autopsy in this group despite antifungal treatment.
How It Was Studied
This is a multi-centre, open-label, phase III superiority randomised controlled trial embedded within existing routine CrAg screening programmes in South Africa and Tanzania. Eligible participants are adults with advanced HIV disease who test positive for CrAg in blood but have no evidence of meningitis at enrolment. A total of 600 participants are being randomised equally, 300 per arm, to receive either fluconazole 1200 mg/day plus flucytosine 100 mg/kg/day or fluconazole 1200 mg/day alone for 14 days, after which all participants transition to fluconazole consolidation and maintenance therapy according to local guidelines. The primary endpoint is all-cause mortality at six months, with secondary endpoints covering time to death, cryptococcal meningitis-free survival, incidence of symptomatic meningitis, grade 3 or 4 adverse events, efficacy stratified by baseline CrAg titre, and health economic outcomes including cost per life year saved.
What Was Observed
- This is a protocol publication and no efficacy or safety results are yet available. The trial is ongoing, and all findings reported here describe design parameters rather than observed outcomes.
- The trial is powered to detect a 40% relative reduction in all-cause mortality at six months, with 91% power across 600 participants (300 per arm), reflecting the magnitude of benefit the investigators consider clinically meaningful and plausible based on the biological rationale for combination treatment.
- Secondary outcomes include a health economic analysis measuring costs per life year saved from both health service and household perspectives, recognising that implementability and affordability are essential considerations for adoption in high-burden, resource-constrained settings.
Why This Matters
Cryptococcal meningitis remains a leading cause of HIV-associated mortality in sub-Saharan Africa despite the scale-up of antiretroviral therapy, and CrAg screening programmes represent a critical opportunity to intervene before meningitis develops. The fact that fluconazole-treated antigenaemic individuals continue to die from cryptococcal disease — as documented in autopsy studies cited in the abstract — signals that the current WHO-recommended standard of care may be insufficient for this population. If the combination regimen proves superior, an all-oral, generically available, field-deployable treatment option could redefine pre-emptive management of CrAg-positive individuals identified through screening.
How to Read This Result
Because this is a protocol paper with no efficacy data yet reported, no conclusions about the comparative effectiveness or safety of fluconazole plus flucytosine can be drawn; the actual treatment effect, and whether the 40% mortality reduction target is achievable, remains entirely unknown until trial completion and analysis.
Limitations
The open-label design, in which neither participants nor clinicians are blinded to treatment allocation, introduces the possibility of performance bias in clinical management decisions. Most importantly, this publication presents only the study protocol and no results are yet available, meaning no inference about efficacy or harm is currently possible. The trial is conducted exclusively in South Africa and Tanzania, which may limit direct generalisability to other high-burden settings with different health system infrastructures, patient populations, or patterns of advanced HIV disease presentation.